AMMI Canada/Accelerate Diagnostics Co-developed Accredited Workshop:

Antimicrobial Stewardship: Rapid Phenotypic Antibiotic Susceptibilities in the Management of Patients with Bacteremia

Friday, May 5, 2017
1800–1930

(Registration and Dinner 1800–1830)

Birchwood Ballroom – Sheraton Centre Toronto
NOTE: Pre-registration is required, to a maximum of 100 people. No walk ins will be permitted once maximum is reached.

Register today ›
Visit us at booth 218!

  • Experience the technology through our interactive demonstration
  • Learn about the reporting features of Accelerate Pheno™ System
  • See the instrument and user interface in action
  • One-on-one meetings with key team members

Speakers:
Moderator
Edith Blondel-Hill, MD, FRCPC

Medical Microbiology/Infectious Diseases Specialist
Larissa Yarr Medical Microbiology Laboratory
Medical Director Antimicrobial Stewardship - Interior Health
Kelowna, BC

Dr. Edith Blondel-Hill trained at the University of Alberta, Edmonton, Alberta, Canada and received specialty training in internal medicine, infectious diseases and medical microbiology. She started her career at the Royal Alexandra Hospital in Edmonton as an infectious diseases consultant and medical microbiologist and moved to Dynacare Kasper Medical Laboratories in 1997. She moved to British Columbia in 2003 where she worked as a microbiology consultant at BC Children’s Hospital in Vancouver until 2008. She is currently the microbiology consultant for Interior Health and is located at the Kelowna General Hospital in Kelowna, British Columbia. She has a long interest in antimicrobial utilization, chairing various antimicrobial advisory committees in Alberta and British Columbia as well as being involved in guideline and policy development for antibiotic use and prescribing. She is co-author of the Bugs and Drugs – Antimicrobial Reference Book and the medical director of the Do Bugs Need Drugs? program, an educational program to address antimicrobial resistance. Her major interests include mechanisms of resistance and susceptibility testing.

Speaker
Nick Daneman MD, FRCPC, MSc

Associate Professor, Faculty of Medicine
University of Toronto

Dr. Nick Daneman is a clinician scientist in the division of infectious diseases at Sunnybrook Health Sciences Centre, is cross-appointed in the institute of Health Policy Management and Evaluation, at the University of Toronto, and is an adjunct scientist at the Institute for Clinical Evaluative Sciences.  He is supported by a Clinician Scientist salary award from the Canadian Institute for Health Research.  Using hospital, clinical trial, and population-based data sources, his research program aims to optimize the treatment and prevention of healthcare associated infection, with overlapping themes including antibiotic stewardship, critical care infections and C.difficile.

Speaker
Susan M. Poutanen MD, MPH, FRCPC

Microbiology & Infectious Disease Consultant
University Health Network & Mount Sinai Hospital
Department of Microbiology

Dr. Poutanen is a Medical Microbiologist and Infectious Diseases Physician at Mount Sinai Hospital & University Health Network in Toronto, Canada and an associate professor in the Department of Laboratory Medicine and Pathobiology and Department of Medicine at the University of Toronto.

Dr. Poutanen received her Medical Degree from the University of Toronto in 1996 and completed Internal Medicine and Medical Microbiology Residencies at the University of Toronto and an Infectious Diseases Fellowship at Stanford University, California. She received her Masters of Public Health with a focus on Epidemiology from the University of California, Berkeley in 2002.

Her broad research interests include: the epidemiology and detection of antimicrobial resistance; the diagnosis of and preparedness for emerging infectious diseases; the use of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and other emerging indications; and the optimization of microbiology laboratory practices to support antimicrobial stewardship and patient care.


Workshop:

The rapid global spread of multi-resistant bacteria and resulting loss of antibiotic effectiveness increases the risk of initial inappropriate antibiotic therapy for patients with serious infections in Canadian hospitals. This program will focus on antibiotic management for patients with bacteremia and will review the challenges facing clinicians and stewardship teams in utilizing antimicrobial susceptibility results from the clinical microbiology laboratory to improve patient outcomes. The program will also review recent advances in susceptibility testing that are currently available for clinical use. The value of rapid susceptibility results in management of patients with bacteremia in the Canadian healthcare environment will be discussed with emphasis on antimicrobial optimization, escalation and de-escalation.


Agenda:
1800–1825

Registration and Dinner

1825–1830

Welcome Remarks and Introduction

1830–1855

Clinical Challenges and Antibiotic Stewardship Issues Related to the Management of Patients with Bacteremia
Nick Daneman

Objectives:

  1. Describe the clinical challenges in utilizing antibiotic susceptibility results in the management of patients with bacteremia.
  2. Discuss how the clinical management of bacteremic patients is impacted by the Canadian National Action Plan for Antimicrobial Stewardship.
  3. Consider the effect of reducing the time to effective therapy and time to antibiotic optimization on bacteremic patient outcomes.
1855–1920

Rapid Phenotypic Susceptibility Platforms: Scientific Principles and Clinical Utility
Susan M. Poutanen

Objectives:

  1. Discuss recent advances in rapid phenotypic susceptibility testing options and their scientific principles compared to genotypic methods.
  2. Describe the impact of rapid phenotypic susceptibility testing platforms on antimicrobial stewardship in patients with bacteremia.

Recent Publications

May 22, 2017

Evaluation of Accelerate Pheno™ System in a Clinical Setting: Comparison of Identification and Antibiotic Susceptibility Test Results of 224 Prospective Positive Blood Cultures to Standard Laboratory Methods at Detroit Medical Center
ECCMID 2017

May 22, 2017

Predicting the hVISA Phenotype Using a Novel in vitro Real-time Assessment of S. aureus Division Rates
ECCMID 2017

May 22, 2017

Evaluation of the Accelerate Pheno™ system versus current blood culture ID/AST methods and potential impact on antimicrobial stewardship and patient management
ECCMID 2017

Jun 18, 2016

Reproducibility of the Accelerate ID/AST Blood Culture Assay at Multiple Clinical Sites
ASM 2016

See all publications

Learn about our

Technology

What it’s like

Inside Accelerate